Nutriband (NTRB) Stock Overview
Develops a portfolio of transdermal pharmaceutical products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
NTRB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nutriband Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.53 |
| 52 Week High | US$11.78 |
| 52 Week Low | US$3.72 |
| Beta | 1.29 |
| 1 Month Change | -13.40% |
| 3 Month Change | 0.46% |
| 1 Year Change | 53.65% |
| 3 Year Change | 72.98% |
| 5 Year Change | -10.48% |
| Change since IPO | 15.43% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Nutriband Inc.'s (NASDAQ:NTRB) CEO Is Reasonable
Jan 17
Is Nutriband (NASDAQ:NTRB) A Risky Investment?
Mar 31Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?
Sep 13Nutriband GAAP EPS of -$0.12, revenue of $0.5M
Sep 08Nutriband opens a new branch in Ecuador with plans to expand into the South American market
Jul 22Nutriband: Advancing Transdermal Delivery Of Injectable Drugs
Nov 01Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?
Oct 06Shareholder Returns
| NTRB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.5% | -0.2% | 2.3% |
| 1Y | 53.6% | -13.3% | 17.2% |
Return vs Industry: NTRB exceeded the US Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: NTRB exceeded the US Market which returned 17.5% over the past year.
Price Volatility
| NTRB volatility | |
|---|---|
| NTRB Average Weekly Movement | 14.6% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTRB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NTRB's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Serguei Melnik | www.nutriband.com |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.
Nutriband Inc. Fundamentals Summary
| NTRB fundamental statistics | |
|---|---|
| Market cap | US$71.35m |
| Earnings (TTM) | -US$9.97m |
| Revenue (TTM) | US$2.40m |
Is NTRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTRB income statement (TTM) | |
|---|---|
| Revenue | US$2.40m |
| Cost of Revenue | US$1.57m |
| Gross Profit | US$830.51k |
| Other Expenses | US$10.80m |
| Earnings | -US$9.97m |
Last Reported Earnings
Apr 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 34.63% |
| Net Profit Margin | -415.83% |
| Debt/Equity Ratio | 3.5% |
How did NTRB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/28 18:22 |
| End of Day Share Price | 2025/08/28 00:00 |
| Earnings | 2025/04/30 |
| Annual Earnings | 2025/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nutriband Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | NOBLE Capital Markets, Inc. |